News

Deal Announcements

CytoPherx Closes Venture Capital Round

Thursday, January 5, 2012 5:51:00 AM PDT | VentureDeal Staff
   Ann Arbor, Michigan  --  Medical device company CytoPherx has garnered $34 million in a new round of venture capital investment.

CytoPherx is developing a proprietary selective cytopheresis system to provide anti-inflammatory therapy for kidney injury.

A large syndicate of venture capital and strategic investors participated in the round.

The company said it would use the financing to complete US clinical trials of its anti-inflammatory therapy for acute kidney injury.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1